Voices
Argument, memoir, and dissent.
A Dutch ethics team re-reads the dementia euthanasia wish as an outward-facing act, aimed at sparing a partner. Their argument puts pressure on the one thing the law insists on: a request made alone.
A new legal analysis walks through every place in the world where voluntary assisted dying is lawful and finds that a dementia diagnosis, by itself, almost never clears the bar, even in the handful of countries that allow a person to request it in advance.
A registry study of every euthanasia case reported in Belgium since 2002 finally puts arithmetic where the argument usually runs on assertion. Psychiatric cases kept pace with the rest of the practice. Dementia cases ran a little ahead of it. Both numbers are far smaller than the avalanche the debate keeps predicting.
Doctors, lawyers and families have argued for years about voluntary assisted dying and dementia in Australia. Two small studies finally put the question to the people whose deaths are under debate, and printed the answers.
Sixteen Taiwanese specialists sat down and described, in their own words, how a dementia diagnosis actually gets told: trimmed, timed, sometimes split between the patient and the family. A grounded theory study in BMC Geriatrics puts the old truth-telling argument back on the table, with the clock in the room.
Two small Australian studies, a survey of 36 people living with dementia and follow-up interviews with 12 of them, put an excluded group on the record about voluntary assisted dying. Their argument is about being believed, not about medicine.
A leadership paper published in June sets provider and patient perspectives side by side. It is the record of a conversation, not a survey, and that distinction is the story.
An op-ed in The Fulcrum argues aid-in-dying statutes are built for cancer timelines, not for capacity that goes first. It is an argument, not evidence, and the distinction matters.
A Comment in Communications Medicine argues that continued clinical use of "dementia" is a public health harm. It is an argument, not a study, and it is worth reading closely.
A Viewpoint in JAMA Neurology argues that memory clinic services should be differentiated by purpose, matching a patient's needs and complexity to the right level of oversight. It is an argument about plumbing, not a trial, and it says so.
A Hastings Center Report essay argues that people living with dementia expose the limits of narrative-medicine teaching built around a coherent first-person account, and calls for training clinicians to read metaphor and the body instead. It is an argument, not a trial.
An open access paper in the Journal of Law, Medicine & Ethics argues that people with Alzheimer's should be able to sign themselves into future research before they lose capacity. The objection it takes on is older than the trials: that the signer and the subject may not be the same person.
A peer reviewed philosophy paper published in June builds its case from memoirs written by people with dementia, and argues that the person with the diagnosis is grieving too, not only the family around them.
Five authors in the Journal of Law, Medicine & Ethics say the dementia directives now in circulation have holes in them. Their answer is a new form that tries to bind a future self who will not remember signing it.
JAMA Neurology's July issue carries a Humanities essay titled "Dementia: The Physician Caregiver and Identity". The journal's own summary says the author cared for her husband. Here is what that publication does, and does not, tell a family.
Appeal panels found NICE's handling of carer quality of life and unpaid care costs unreasonable. The appraisals of lecanemab and donanemab went back to committee, and in August 2026 they are still open.
Cochrane's April review of amyloid antibodies pooled 17 trials and found little to no benefit. Two of those trials tested the only drugs now licensed, and that arithmetic is the whole argument.